A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Description
Brief Summary
This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion
study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
Detailed Description
This is a first-in-human, Phase 1/2 multicenter, open-label, dose escalation and expansion
study of AO-176 in patients with solid tumors. Part A of this study will examine escalating
repeat doses of AO-176 monotherapy in patients with select advanced solid tumors, including
epithelial ovarian carcinoma (EOC), which will include primary peritoneal and fallopian tube
carcinoma; squamous cell carcinoma of the head and neck; endometrial carcinoma; castration
resistant prostate cancer; non-small cell lung adenocarcinoma; papillary thyroid carcinoma;
pleural or peritoneal malignant mesothelioma; and gastroesophageal adenocarcinoma, for which
standard therapy proven to provide clinical benefit does not exist or is no longer effective.
Part B and Part C of this study will examine escalating repeat doses of AO-176 in combination
with paclitaxel (Part B) or pembrolizumab (Part C) in platinum-resistant EOC, including
primary peritoneal and fallopian tube carcinoma; endometrial carcinoma; and gastric
adenocarcinoma/gastroesophageal adenocarcinoma.
The monotherapy and combination dose escalation portions of the study utilize a classic 3+3
design, with enrollment of 3 patients per cohort and expansion of the cohort in the event of
a dose-limiting toxicity (DLT).
Once the maximum-tolerated dose (MTD)/recommended phase 2 dose (RP2D) has been established in
dose escalation, tumor-specific dose expansion cohorts will be recruited to further assess
safety and evaluate preliminary efficacy of AO-176 as monotherapy, in combination with
paclitaxel, and in combination with pembrolizumab.
Phase
N/AInclusion and Exclusion Criteria
- Key Inclusion Criteria
- Select advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist, or is no longer effective Part A: - Epithelial ovarian carcinoma (EOC) - Endometrial carcinoma - Castration resistant prostate cancer - Non-small cell lung adenocarcinoma - Papillary thyroid carcinoma - Malignant mesothelioma (pleural or peritoneal) - Gastroesophageal adenocarcinoma - Squamous cell carcinoma of the head and neck Part B and Part C: - Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer) - Endometrial carcinoma - Gastric adenocarcinoma/gastroesophageal adenocarcinoma
- Measurable disease
- ECOG status 0-1
- Resolution of prior-therapy-related adverse effects
- Minimum of 4 weeks or 5 half-lives since last dose of cancer therapy Key Exclusion Criteria:
- Previous hypersensitivity reaction to treatment with another monoclonal antibody
- Unresolved hypersensitivity to paclitaxel or any of its excipients (Part B only). Patients who have been desensitized may participate.
- Part C Only
- History of interstitial lung disease or a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- History of immune mediated colitis, hepatitis, endocrinopathies, nephritis or significant immune mediated skin reactions such as toxic epidermal necrolitis or Stevens -Johnson Syndrome
- History of any autoimmune disease which required systemic therapy* in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) including but not limited to: i. Inflammatory bowel disease (including ulcerative colitis and Crohn's Disease) ii. Rheumatoid arthritis iii. Systemic progressive sclerosis (scleroderma) iv. Systemic lupus erythematosus v. Autoimmune vasculitis (e.g. Wegener's granulomatosis) *Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed)
- Prior treatment with a checkpoint inhibitor (anti-PD-1, PD-L1, CTLA-4 etc.) within 4 weeks prior to the start of study drug
- Prior treatment with a CD47-targeted therapy
- Prior organ or stem cell transplant
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.